Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S1W-15698 · Session 1

Further to the answer to question S1W-12788 by Susan Deacon on 7 February 2001, when Aricept will be made available throughout the National…

Answered Asked by Annabel Goldie Con Lodged 9 May 2001

The question

To ask the Scottish Executive, further to the answer to question S1W-12788 by Susan Deacon on 7 February 2001, when Aricept will be made available throughout the National Health Service in Scotland.

The answer

Answered by Susan Deacon on 22 May 2001 · 13 days after it was lodged, on time

Donepezil (Aricept) has been licensed since 1997 for the treatment of mild to moderate dementia in Alzheimer's disease. The use of this treatment depends on the clinical judgement of the clinician concerned, taking into account advice and evidence about its use. This will include the Health Technology Board for Scotland's Comment of 1 May 2001 on the Final Appraisal from the National Institute for Clinical Excellence on the use of Aricept, rivastigmine (Exelon) and galantamine (Reminyl).

In the Official Report

No contribution in the Official Report cites S1W-15698 by reference.